SoniVie device
SoniVie Ltd, an Israeli medtech startup that is developing a proprietary solution to treat hypertension, completed a $60 million series C round financing led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated. In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
Medtech, along with cybersecurity, seems to be one of the fields that will always be in demand, regardless of recessions. While the world is still reeling from a global financial crisis, Israel Startup Nation firms are still moving forward. For example, Novocure, an Israeli medtech company that develops and sells a treatment using electric fields for various types of cancer, has been seeing success in its studies of cancer treatments.
SoniVie is a medical device company developing TIVUS, the only ultra-sound denervation platform with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease with chronic bronchitis. These diseases affect millions of patients in the United States and Europe. SoniVie has operations in Israel, US and Europe. This minimally invasive investigational procedure can be used to treat patients suffering from hypertension, which impacts millions of people worldwide and substantially increases their risk of heart attack, stroke and kidney failure.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“We are very pleased that this financing round concluded with such a resounding success,” said Tomaso Zambelli, CEO of SoniVie Ltd. “The new investors and the Board of Directors bring significant experience to the Company in the field of Renal Denervation for Hypertension”.
Raphaël Wisniewski of Andera Partners commented, “SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device. We are thrilled to support this talented management together with our syndicate partners and our new board members”.
